Faster access than browser!Similarities between Novartis and Pharmaceutical industry
Novartis and Pharmaceutical industry have 30 things in common (in Unionpedia): Active ingredient, Asthma, AstraZeneca, Attention deficit hyperactivity disorder, Biotechnology, Epilepsy, False Claims Act, Food and Drug Administration, Generic drug, GlaxoSmithKline, Heart failure, Hepatitis B, Hoechst AG, Hoffmann-La Roche, Imatinib, List of pharmaceutical companies, Malaria, Medication, National Health Service, National Institute for Health and Care Excellence, Nobel Prize in Physiology or Medicine, Novartis, Off-label use, Pharmaceutical formulation, Pharmaceutical Research and Manufacturers of America, Pre-clinical development, Psychiatry, Qui tam, TRIPS Agreement, World Trade Organization.
Active ingredient
An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active.
Active ingredient and Novartis · Active ingredient and Pharmaceutical industry ·
Asthma
Asthma is a common long-term inflammatory disease of the airways of the lungs.
Asthma and Novartis · Asthma and Pharmaceutical industry ·
AstraZeneca
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
AstraZeneca and Novartis · AstraZeneca and Pharmaceutical industry ·
Attention deficit hyperactivity disorder
Attention-deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type.
Attention deficit hyperactivity disorder and Novartis · Attention deficit hyperactivity disorder and Pharmaceutical industry ·
Biotechnology
Biotechnology is the broad area of science involving living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use" (UN Convention on Biological Diversity, Art. 2).
Biotechnology and Novartis · Biotechnology and Pharmaceutical industry ·
Epilepsy
Epilepsy is a group of neurological disorders characterized by epileptic seizures.
Epilepsy and Novartis · Epilepsy and Pharmaceutical industry ·
False Claims Act
The False Claims Act, also called the "Lincoln Law") is an American federal law that imposes liability on persons and companies (typically federal contractors) who defraud governmental programs. It is the federal Government's primary litigation tool in combating fraud against the Government. The law includes a qui tam provision that allows people who are not affiliated with the government, called "relators" under the law, to file actions on behalf of the government (informally called "whistleblowing" especially when the relator is employed by the organization accused in the suit). Persons filing under the Act stand to receive a portion (usually about 15–25 percent) of any recovered damages. As of 2012, over 70 percent of all federal Government FCA actions were initiated by whistleblowers. Claims under the law have typically involved health care, military, or other government spending programs, and dominate the list of largest pharmaceutical settlements. The government recovered $38.9 billion under the False Claims Act between 1987 and 2013 and of this amount, $27.2 billion or 70% was from qui tam cases brought by relators.
False Claims Act and Novartis · False Claims Act and Pharmaceutical industry ·
Food and Drug Administration
The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
Food and Drug Administration and Novartis · Food and Drug Administration and Pharmaceutical industry ·
Generic drug
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use, but does not carry the brand name.
Generic drug and Novartis · Generic drug and Pharmaceutical industry ·
GlaxoSmithKline
GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London.
GlaxoSmithKline and Novartis · GlaxoSmithKline and Pharmaceutical industry ·
Heart failure
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs.
Heart failure and Novartis · Heart failure and Pharmaceutical industry ·
Hepatitis B
Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver.
Hepatitis B and Novartis · Hepatitis B and Pharmaceutical industry ·
Hoechst AG
Hoechst AG was a German chemicals then life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999.
Hoechst AG and Novartis · Hoechst AG and Pharmaceutical industry ·
Hoffmann-La Roche
F.
Hoffmann-La Roche and Novartis · Hoffmann-La Roche and Pharmaceutical industry ·
Imatinib
Imatinib, sold under the brand names Gleevec among others, is a medication used to treat cancer.
Imatinib and Novartis · Imatinib and Pharmaceutical industry ·
List of pharmaceutical companies
It is limited to those companies notable enough to have articles in Wikipedia.
List of pharmaceutical companies and Novartis · List of pharmaceutical companies and Pharmaceutical industry ·
Malaria
Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic protozoans (a group of single-celled microorganisms) belonging to the Plasmodium type.
Malaria and Novartis · Malaria and Pharmaceutical industry ·
Medication
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease.
Medication and Novartis · Medication and Pharmaceutical industry ·
National Health Service
The National Health Service (NHS) is the name used for each of the public health services in the United Kingdom – the National Health Service in England, NHS Scotland, NHS Wales, and Health and Social Care in Northern Ireland – as well as a term to describe them collectively.
National Health Service and Novartis · National Health Service and Pharmaceutical industry ·
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health in the United Kingdom, which publishes guidelines in four areas.
National Institute for Health and Care Excellence and Novartis · National Institute for Health and Care Excellence and Pharmaceutical industry ·
Nobel Prize in Physiology or Medicine
The Nobel Prize in Physiology or Medicine (Nobelpriset i fysiologi eller medicin), administered by the Nobel Foundation, is awarded once a year for outstanding discoveries in the fields of life sciences and medicine.
Nobel Prize in Physiology or Medicine and Novartis · Nobel Prize in Physiology or Medicine and Pharmaceutical industry ·
Novartis
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.
Novartis and Novartis · Novartis and Pharmaceutical industry ·
Off-label use
Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.
Novartis and Off-label use · Off-label use and Pharmaceutical industry ·
Pharmaceutical formulation
Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances, including the active drug, are combined to produce a final medicinal product.
Novartis and Pharmaceutical formulation · Pharmaceutical formulation and Pharmaceutical industry ·
Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced), formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States founded in 1958.
Novartis and Pharmaceutical Research and Manufacturers of America · Pharmaceutical Research and Manufacturers of America and Pharmaceutical industry ·
Pre-clinical development
In drug development, preclinical development, also named preclinical studies and nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data are collected.
Novartis and Pre-clinical development · Pharmaceutical industry and Pre-clinical development ·
Psychiatry
Psychiatry is the medical specialty devoted to the diagnosis, prevention and treatment of mental disorders.
Novartis and Psychiatry · Pharmaceutical industry and Psychiatry ·
Qui tam
In common law, a writ of qui tam is a writ whereby a private individual who assists a prosecution can receive all or part of any penalty imposed.
Novartis and Qui tam · Pharmaceutical industry and Qui tam ·
TRIPS Agreement
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO).
Novartis and TRIPS Agreement · Pharmaceutical industry and TRIPS Agreement ·
World Trade Organization
The World Trade Organization (WTO) is an intergovernmental organization that regulates international trade.
Novartis and World Trade Organization · Pharmaceutical industry and World Trade Organization ·
The list above answers the following questions
- What Novartis and Pharmaceutical industry have in common
- What are the similarities between Novartis and Pharmaceutical industry
Novartis and Pharmaceutical industry Comparison
Novartis has 316 relations, while Pharmaceutical industry has 257. As they have in common 30, the Jaccard index is 5.24% = 30 / (316 + 257).
References
This article shows the relationship between Novartis and Pharmaceutical industry. To access each article from which the information was extracted, please visit:
